An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.

NCT Number	NCT07468526
Lead Sponsor	Menzies School of Health Research Collaborators: Curtin University, University of Melbourne, Papua New Guinea Institute of Medical Research, Arba Minch University, Jimma University, Universitas Sumatera Utara, Aga Khan University, PathWest Laboratory Medicine WA
Conditions	Malaria
Enrollment	1,019 participants
Start Date	2026-06-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-12